Chinese General Practice ›› 2023, Vol. 26 ›› Issue (11): 1369-1374.DOI: 10.12114/j.issn.1007-9572.2022.0712
• Original Research • Previous Articles Next Articles
Received:
2022-07-20
Revised:
2022-12-20
Published:
2023-04-15
Online:
2023-02-01
Contact:
SHEN Shanmei
About author:
通讯作者:
沈山梅
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0712
组别 | 例数 | 一般资料 | 生化指标 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 年龄(岁) | BMI (kg/m2) | 收缩压(mm Hg) | 舒张压(mm Hg) | 血钙(mmol/L) | 血磷(mmol/L) | 血钾(mmol/L) | AKP (U/L) | Scr (μmol/L) | eGFR 〔ml·min-1·(1.73 m2)-1〕 | UA (μmol/L) | PTH (pmol/L) | ||
健康对照组 | 50 | 22/28 | 46.9±15.4 | 24.1±4.1 | 123±19 | 77±8 | 2.42±0.19 | 1.03±0.16 | 3.93±0.19 | 65.9±19.6 | 55.4±15.7 | 129.8±30.0 | 98.2±73.1 | 5.2±1.7 |
正常血钙组 | 36 | 12/24 | 51.5±14.1 | 24.2±3.4 | 133±20a | 83±8a | 2.62±0.12 | 0.84±0.19a | 4.02±0.23 | 105.7±68.9a | 56.5±13.8 | 118.1±33.1 | 332.1±86.4a | 33.0±26.2a |
高钙组 | 117 | 34/83 | 52.5±15.8 | 23.6±3.8 | 130±20 | 86±12 | 3.08±0.30b | 0.71±0.18ab | 4.15±1.47 | 265.3±88.5ab | 76.9±43.9ab | 104.1±40.1b | 396.8±123.4ab | 58.8±47.6ab |
F(χ2)值 | 3.510c | 2.339 | 0.908 | 3.183 | 12.860 | 136.282 | 57.740 | 0.715 | 154.204 | 9.417 | 9.074 | 137.272 | 36.150 | |
P值 | 0.173 | 0.100 | 0.602 | 0.044 | <0.001 | <0.001 | <0.001 | 0.490 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | |
组别 | 糖代谢指标 | 骨代谢指标 | 骨密度(g/cm3) | |||||||||||
HbA1c(%) | FPG(mmol/L) | FIns(μU/ml) | HOMA-IR | P1NP(μg/L) | β-CTX(μg/L) | OC(μg/L) | CT(ng/L) | L1~4 | 股骨颈 | |||||
健康对照组 | 5.27±1.42 | 4.79±0.65 | 10.12±6.31 | 2.18±1.84 | 59.73±34.73 | 0.51±0.27 | 17.11±5.61 | 2.00±0.70 | 1.23±0.12 | 1.01±0.13 | ||||
正常血钙组 | 5.72±0.15a | 5.13±0.81 | 12.87±8.24 | 5.83±2.09a | 82.40±29.40a | 0.97±0.36a | 46.28±23.95a | 4.59±2.89a | 0.93±0.16a | 0.95±0.12a | ||||
高钙组 | 5.46±0.32 | 5.31±1.52a | 16.12±10.83a | 6.08±3.00a | 171.39±38.52ab | 1.50±0.92ab | 77.28±33.30ab | 4.93±2.93a | 0.87±0.11a | 0.72±0.10ab | ||||
F(χ2)值 | 3.802 | 3.045 | 7.402 | 40.930 | 201.000 | 33.823 | 87.733 | 23.579 | 145.263 | 142.226 | ||||
P值 | 0.024 | 0.050 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of general data and biochemical indices among control group,hypercalcemia PHPT group and NCPHPT group
组别 | 例数 | 一般资料 | 生化指标 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 年龄(岁) | BMI (kg/m2) | 收缩压(mm Hg) | 舒张压(mm Hg) | 血钙(mmol/L) | 血磷(mmol/L) | 血钾(mmol/L) | AKP (U/L) | Scr (μmol/L) | eGFR 〔ml·min-1·(1.73 m2)-1〕 | UA (μmol/L) | PTH (pmol/L) | ||
健康对照组 | 50 | 22/28 | 46.9±15.4 | 24.1±4.1 | 123±19 | 77±8 | 2.42±0.19 | 1.03±0.16 | 3.93±0.19 | 65.9±19.6 | 55.4±15.7 | 129.8±30.0 | 98.2±73.1 | 5.2±1.7 |
正常血钙组 | 36 | 12/24 | 51.5±14.1 | 24.2±3.4 | 133±20a | 83±8a | 2.62±0.12 | 0.84±0.19a | 4.02±0.23 | 105.7±68.9a | 56.5±13.8 | 118.1±33.1 | 332.1±86.4a | 33.0±26.2a |
高钙组 | 117 | 34/83 | 52.5±15.8 | 23.6±3.8 | 130±20 | 86±12 | 3.08±0.30b | 0.71±0.18ab | 4.15±1.47 | 265.3±88.5ab | 76.9±43.9ab | 104.1±40.1b | 396.8±123.4ab | 58.8±47.6ab |
F(χ2)值 | 3.510c | 2.339 | 0.908 | 3.183 | 12.860 | 136.282 | 57.740 | 0.715 | 154.204 | 9.417 | 9.074 | 137.272 | 36.150 | |
P值 | 0.173 | 0.100 | 0.602 | 0.044 | <0.001 | <0.001 | <0.001 | 0.490 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | |
组别 | 糖代谢指标 | 骨代谢指标 | 骨密度(g/cm3) | |||||||||||
HbA1c(%) | FPG(mmol/L) | FIns(μU/ml) | HOMA-IR | P1NP(μg/L) | β-CTX(μg/L) | OC(μg/L) | CT(ng/L) | L1~4 | 股骨颈 | |||||
健康对照组 | 5.27±1.42 | 4.79±0.65 | 10.12±6.31 | 2.18±1.84 | 59.73±34.73 | 0.51±0.27 | 17.11±5.61 | 2.00±0.70 | 1.23±0.12 | 1.01±0.13 | ||||
正常血钙组 | 5.72±0.15a | 5.13±0.81 | 12.87±8.24 | 5.83±2.09a | 82.40±29.40a | 0.97±0.36a | 46.28±23.95a | 4.59±2.89a | 0.93±0.16a | 0.95±0.12a | ||||
高钙组 | 5.46±0.32 | 5.31±1.52a | 16.12±10.83a | 6.08±3.00a | 171.39±38.52ab | 1.50±0.92ab | 77.28±33.30ab | 4.93±2.93a | 0.87±0.11a | 0.72±0.10ab | ||||
F(χ2)值 | 3.802 | 3.045 | 7.402 | 40.930 | 201.000 | 33.823 | 87.733 | 23.579 | 145.263 | 142.226 | ||||
P值 | 0.024 | 0.050 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 直径(cm) | 左侧/右侧 | 上极/下极 | 异位〔n(%)〕 | 多腺体病变〔n(%)〕 |
---|---|---|---|---|---|---|
正常血钙组 | 36 | 2.06±1.00 | 25/15 | 11/29 | 0 | 4(11.11) |
高钙组 | 117 | 2.23±1.04 | 52/61 | 34/79 | 4(3.42) | 0 |
t(χ2)值 | -0.979 | 3.210a | 0.095a | — | — | |
P值 | 0.329 | 0.073 | 0.757 | 0.573 | 0.004 |
Table 2 Comparison of imaging features between NCPHPT group and hypercalcemia PHPT group
组别 | 例数 | 直径(cm) | 左侧/右侧 | 上极/下极 | 异位〔n(%)〕 | 多腺体病变〔n(%)〕 |
---|---|---|---|---|---|---|
正常血钙组 | 36 | 2.06±1.00 | 25/15 | 11/29 | 0 | 4(11.11) |
高钙组 | 117 | 2.23±1.04 | 52/61 | 34/79 | 4(3.42) | 0 |
t(χ2)值 | -0.979 | 3.210a | 0.095a | — | — | |
P值 | 0.329 | 0.073 | 0.757 | 0.573 | 0.004 |
组别 | 例数 | 腺瘤 | 腺癌 | 增生 | 侵犯包膜 | 细胞异型性 |
---|---|---|---|---|---|---|
正常血钙组 | 36 | 34(94.44) | 0 | 2(5.56) | 0 | 1(2.78) |
高钙组 | 117 | 104(88.89) | 3(2.56) | 10(8.55) | 15(12.82) | 16(13.68) |
Table 3 Comparison of pathology features between NCPHPT group and hypercalcemia PHPT group
组别 | 例数 | 腺瘤 | 腺癌 | 增生 | 侵犯包膜 | 细胞异型性 |
---|---|---|---|---|---|---|
正常血钙组 | 36 | 34(94.44) | 0 | 2(5.56) | 0 | 1(2.78) |
高钙组 | 117 | 104(88.89) | 3(2.56) | 10(8.55) | 15(12.82) | 16(13.68) |
自变量 | 变量名 | 赋值 |
---|---|---|
性别 | X1 | 男=1,女=2 |
年龄(岁) | X2 | ≤40=1,40~49=2,50~59=3,≥60=4 |
BMI(kg/m2) | X3 | <18.5=1,18.5~23.9=2,24.0~27.9=3,≥28=4 |
高血压病史 | X4 | 是=1,否=2 |
合并泌尿系结石 | X5 | 是=1,否=2 |
合并骨密度异常 | X6 | 骨量减少=1,骨质疏松=2,骨量正常=3 |
血钙(mmol/L) | X7 | ≤2.75=1,>2.75=2 |
血磷(mmol/L) | X8 | <0.96=1,0.96~1.62=2,>1.62=3 |
血钾(mmol/L) | X9 | <3.5=1,3.5~5.5=2,>5.5=3 |
AKP(U/L) | X10 | ≤185=1,>185=2 |
Scr(μmol/L) | X11 | ≤106=1,>106=2 |
eGFR〔ml·min-1·(1.73 m2)-1〕 | X12 | 60~90=1,>90=2 |
UA (μmol/L) | X13 | ≤420=1,>420=2 |
HbA1c(%) | X14 | ≤6=1,6.1~6.4=2,≥6.5=3 |
FPG (mmol/L) | X15 | <6.1=1,6.1~6.9=2,≥7.0=3 |
P1NP (μg/L) | X16 | 实测值 |
β-CTX(μg/L) | X17 | 实测值 |
OC (μg/L) | X18 | ≤70=1,>70=2 |
CT (ng/L) | X19 | <2=1,≥2=2 |
Table 4 Main variables and corresponding assignments for Logistic regression
自变量 | 变量名 | 赋值 |
---|---|---|
性别 | X1 | 男=1,女=2 |
年龄(岁) | X2 | ≤40=1,40~49=2,50~59=3,≥60=4 |
BMI(kg/m2) | X3 | <18.5=1,18.5~23.9=2,24.0~27.9=3,≥28=4 |
高血压病史 | X4 | 是=1,否=2 |
合并泌尿系结石 | X5 | 是=1,否=2 |
合并骨密度异常 | X6 | 骨量减少=1,骨质疏松=2,骨量正常=3 |
血钙(mmol/L) | X7 | ≤2.75=1,>2.75=2 |
血磷(mmol/L) | X8 | <0.96=1,0.96~1.62=2,>1.62=3 |
血钾(mmol/L) | X9 | <3.5=1,3.5~5.5=2,>5.5=3 |
AKP(U/L) | X10 | ≤185=1,>185=2 |
Scr(μmol/L) | X11 | ≤106=1,>106=2 |
eGFR〔ml·min-1·(1.73 m2)-1〕 | X12 | 60~90=1,>90=2 |
UA (μmol/L) | X13 | ≤420=1,>420=2 |
HbA1c(%) | X14 | ≤6=1,6.1~6.4=2,≥6.5=3 |
FPG (mmol/L) | X15 | <6.1=1,6.1~6.9=2,≥7.0=3 |
P1NP (μg/L) | X16 | 实测值 |
β-CTX(μg/L) | X17 | 实测值 |
OC (μg/L) | X18 | ≤70=1,>70=2 |
CT (ng/L) | X19 | <2=1,≥2=2 |
自变量 | B | SE | Wald χ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
合并泌尿系结石 | 0.901 | 0.243 | 13.744 | 0.011 | 2.462(1.178,3.552) |
骨密度异常 | -0.916 | 0.477 | 3.686 | 0.055 | 0.400(0.157,1.019) |
血磷 | -3.612 | 1.021 | 12.510 | 0.031 | 0.027(0.001,0.711) |
AKP | 1.033 | 0.312 | 10.958 | 0.037 | 2.809(1.422,8.020) |
Scr | 0.021 | 0.010 | 4.041 | 0.054 | 1.021(1.001,1.042) |
UA | 0.068 | 0.120 | 0.327 | 0.567 | 1.071(0.827,1.354) |
OC | 0.013 | 0.022 | 0.346 | 0.556 | 1.013(0.970,1.058) |
CT | 0.092 | 0.208 | 0.194 | 0.659 | 1.096(0.719,1.647) |
Table 5 Multivariate Logistic regression analysis of the risk factors for NCPHPT
自变量 | B | SE | Wald χ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
合并泌尿系结石 | 0.901 | 0.243 | 13.744 | 0.011 | 2.462(1.178,3.552) |
骨密度异常 | -0.916 | 0.477 | 3.686 | 0.055 | 0.400(0.157,1.019) |
血磷 | -3.612 | 1.021 | 12.510 | 0.031 | 0.027(0.001,0.711) |
AKP | 1.033 | 0.312 | 10.958 | 0.037 | 2.809(1.422,8.020) |
Scr | 0.021 | 0.010 | 4.041 | 0.054 | 1.021(1.001,1.042) |
UA | 0.068 | 0.120 | 0.327 | 0.567 | 1.071(0.827,1.354) |
OC | 0.013 | 0.022 | 0.346 | 0.556 | 1.013(0.970,1.058) |
CT | 0.092 | 0.208 | 0.194 | 0.659 | 1.096(0.719,1.647) |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
中华医学会骨质疏松和骨矿盐疾病分会,中华医学会内分泌分会代谢性骨病学组. 原发性甲状旁腺功能亢进症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志,2014,7(3):187-198.
|
[7] |
高钙血症诊治指南(讨论稿)[C]. 中华医学会第四次全国骨质疏松和骨矿盐疾病学术会议,2006:29-32.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[2] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[3] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[4] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[5] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[6] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[7] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[8] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[9] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[10] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[11] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[12] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[13] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
[14] | WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069. |
[15] | YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||